CAMP4 Therapeutics Corp (CAMP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.72-0.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CAMP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -43.8% |
| Our one-year growth estimate | diamond | 0.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 44.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
CAMP — private placement
Dated 2026-08-04
Entry into a Material Definitive Agreement. As previously disclosed in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “Commission”) on September 10, 2025, CAMP4 Therapeutics Corporation (the “Company”) entered into a Securities Purchase Agreement, dated September 9, 2025 (the “Original Agreement”), with certain accredited investors named therein (each, an “Investor” and collectively, the “Investors”), pursuant to which the Company agreed to sell to…
Why it matters: More cleared sites could widen trial access and enrollment. Delays could limit the pace of patient enrollment.
Supportive ifCAMP4 reports EU and UK clearance and names at least one new trial site in either region.
Worry ifCAMP4 reports that EU or UK filings are rejected, withdrawn, or delayed beyond its stated trial plans.
Why it matters: The trial will test CMP-002 in people for the first time. Safety and dose findings will show whether it can move past early testing.
Watch forCAMP4 reports no safety issue that limits the dose. It also shows higher SYNGAP1 protein or another stated trial measure as doses rise.
Also watch forCAMP4 reports a serious drug-related safety issue, stops dosing, or pauses the trial.
Why it matters: New results could add support for CMP-002 beyond the trial start. A failure to repeat earlier findings would weaken that support.
Watch forCAMP4 reports new data from a preclinical model. CMP-002 raises SYNGAP protein or improves seizure measures.
Also watch forCAMP4 reports that new tests fail to show a protein increase or seizure improvement.
Why it matters: Starting the first patient trial would meet CAMP4's main near-term goal. A delay would push back its first human data.
Supportive ifCAMP4 announces the first patient has been enrolled or dosed by December 31, 2026.
Worry ifCAMP4 reports no trial start by December 31, 2026, or moves the start beyond Q4 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$299 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $867 loss on $10,000 · 8.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,778 loss on $10,000 · 57.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: CAMP4 reports losses and relies on cash to fund its trials. A shorter runway could raise pressure for more funding.
Worry ifCAMP4 cuts its cash runway estimate to a date before the end of 2028.
Less concerning ifCAMP4 keeps its cash runway estimate through the end of 2028 and reports cash in line with its planned trial work.